Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics

Molecular Diagnosis and Therapy

Volumn 11, Issue 3, 2007, Pages 171-181

  Siew, Hua Gan ^a   Ismail, Rusli ^b   Adnan, Wan Aasim Wan ^a   Zulmi, Wan ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TRAMADOL;

ADOLESCENT; ADULT; ANALGESIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NAUSEA; PAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; VISUAL ANALOG SCALE; VOMITING; WILD TYPE; XEROSTOMIA;

EID: 34250872182     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256239     Document Type: Article

References (46)

1. Raffa RB, Friderichs E, Reimann W, et al. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85
2. Lewis KS, Han NH. Tramadol: a new centrally-acting analgesia. Am J Health Syst Pharm 1997; 54: 643-52
3. Lee R, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313-40
4. Eichelbaum M, Evert B. Influence of pharmacogenetic on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23: 983-5
5. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96
6. Ingelman-Sundberg M, Oscarson M, McLellan RA, et al. Polymorphic human cytochrome P450 enzymes, an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-9
7. Linder MW, Valdes R. Pharmacogenetics in the practise of laboratory medicine. Mol Diagn 1999; 4: 365-79
8. Wolf CR, Smith G. Pharmacogenetics: impact of genomics on healthcare. Br Med Bull 1999; 55 (2): 366-86
9. Teh LK, Ismail R, Yusof R, et al. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26: 1-7
10. Leathart JBS, London SJ, Steward A, et al. CYP2D6 phenotype-genotype relationships in African-American and Caucasians in Los Angeles. Pharmacogenetics 1998; 8: 529-41
11. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-6
12. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24 (2): 75-85
13. Budd K, Langford R. Tramadol revisited. Br J Anaesth 1999; 82: 493-5
14. Bamigbade TA, Langford RM. Tramadol hydrochloride: an overview of current use. Hosp Med 1998; 59 (5): 373-6
15. Austin KL, Stapleton JV, Mather LE. Multiple intramuscular injections: a major source of variability in analgesic response to meperidine. Pain 1980; 8: 47-62
16. Bingle JG, O'Connor TP, Evans WO, et al. The effect of "detailing" on physician's behaviour for postsurgical narcotic analgesia. Pain 1991; 45: 171-3
17. Oates JDL, Snowdon SL, Jayson DWH. Failure of pain relief after surgery. Anaesthesia 1994; 49: 755-8
18. Sunshine A. New clinical experience with tramadol. Drugs 1994; 47 Suppl. 1: 9-18
19. Lehmann KA. Tramadol for the management of acute pain. Drugs 1994; 47 Suppl. 1: 19-32
20. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994; 46 Suppl. 1: 417-24
21. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450-2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcome in psychiatry. Clin Pharmacol Ther 1996; 60: 522-34
22. Armstrong M, Daly AK, Blennerhassett R, et al. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-6
23. Spina E, Gitto C, Avenso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-8
24. Jelliffe R, Bayard D, Milman M. Achieving target goals most precisely using nonparametric compartmental models and multiple model: design of dosage regimens. Ther Drug Monit 2000; 22: 346-53
25. Jelliffe R, Schumitzky A, Bayard D, et al. Model-based, goal-oriented individualised drug therapy: linkage of population modelling, new "multiple model" dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet 1998; 34: 57-77
26. Gan SH, Ismail R, Wan Adnan WA, et al. Population pharmacokinetic modeling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther 2004; 29: 455-63
27. Pickard NA. Collection and handling of patient specimens. In: Kaplan LA, Pesce AJ, editors. Clinical chemistry: theory, analysis and correlation. Toronto (ON): CV Mosby Co., 1990: 40-8
28. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P450 2D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46 (3): 452-9
29. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-32
30. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor-metabolizer associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-23
31. Tyndale R, Aoyama T, Broly F, et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1: 26-32
32. Masimirembwa C, Persson I, Bertilsson L, et al. A novel mutant variant of CYP2D6 gene (CYP2D6*17) common in a Black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713-9
33. Chou WH, Yan FX, de Leon J, et al. Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness: extension of a pilot study. J Clin Psychopharmacol 2000; 20 (2): 246-51
34. Gan SH, Ismail R. Validation of a high-performance liquid chromatography method for tramadol and O-desmethyltramadol in human plasma using solid-phase extraction. J Chromatogr B Biomed Sci Appl 2001; 759: 325-35
35. Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after IM injection in comparison to IV infusion. Int J Clin Pharmacol Ther 1999; 37: 175-83
36. Ho K, Spence J, Murphy MF. Review of pain measurement tools. Ann Emerg Med 1996; 27 (4): 427-32
37. Jelliffe R, Schumitzky A, Van Guilder M, et al. User manual for version 10.7 of the USC*PACK collection of PC programmes. Los Angeles (CA): Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine, 1995: 57-69
38. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and application. Clin Pharmacokinet 1986; 11: 387-401
39. Jelliffe R, Gomis P, Tahani B, et al. A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. Ther Drug Monit 1997; 19: 450-9
40. Chen S, Kumar S, Chou WH. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations. Br J Clin Pharmacol 1997; 44: 303-5
41. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin Pharmacol Ther 1991; 50: 233-8
42. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous gene. Pharmacogenetics 1991; 1: 143-8
43. Lehmann KA, Kratzenberg U, Schroeder-Bark B, et al. Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentration. Clin J Pain 1990; 6: 212-20
44. Tarradell R, Pol O, Farre M, et al. Respiratory and analgesic effects of meperidine and tramadol in patients undergoing orthopaedic surgery. Methods Find Exp Clin Pharmacol 1996; 18 (3): 211-8
45. Follin SL, Charland SL. Acute pain management: operative or medical procedures and trauma. Ann Pharmacother 1997; 31 (9): 1068-76
46. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004; 75 (5): 386-93